2014Coronary artery disease15828 patients

STABILITY

Therapy group: Anti-inflammatory therapy · Therapy: Darapladib vs placebo

In stable coronary heart disease, the Lp-PLA2 inhibitor darapladib did not reduce cardiovascular death, myocardial infarction or stroke compared with placebo.

Published in N Engl J Med (2014)

Question: Can darapladib, a selective oral inhibitor of lipoprotein-associated phospholipase A2, reduce ischemic events in patients with stable coronary heart disease?
Design: Randomized, double-blind, placebo-controlled phase 3 trial of 15828 patients with stable coronary heart disease. Median follow-up was 3.7 years.
Population: Patients with chronic stable coronary heart disease.
Intervention: Darapladib 160 mg orally once daily.
Control: Placebo orally once daily.
Primary outcome: Composite of cardiovascular death, myocardial infarction, or stroke.
Results: The primary end point occurred in 769 of 7924 patients (9.7%) with darapladib and 819 of 7904 (10.4%) with placebo (HR 0.94; 95% CI 0.85 to 1.03; P=0.20). Major coronary events were less frequent with darapladib (9.3% vs. 10.3%; HR 0.90; 95% CI 0.82 to 1.00; P=0.045).
Conclusion: Darapladib did not significantly reduce the risk of the composite of cardiovascular death, myocardial infarction, or stroke in patients with stable coronary heart disease.
Why it matters: This large trial tested Lp-PLA2 inhibition as an anti-inflammatory and anti-atherosclerotic strategy, and its neutral result on the primary end point discouraged the use of this therapeutic pathway in clinical practice.

Card generated automatically with AI from the abstract of the original publication and the trial registry; every figure was checked against those sources. It may contain errors: verify the data at the source before using it for clinical decisions.

Generated on October 18, 2026

Sources

Original publication on PubMed (PMID 24678955) ↗Darapladib for preventing ischemic events in stable coronary heart disease.
Journal article (DOI) ↗
ClinicalTrials.gov record (NCT00799903) ↗

Videos explaining it

EHJ Today - STABILITY Trial

ESC · European Society of Cardiology ↗9:45Video page

Source: European Society of Cardiology · YouTube
Date: 20 Oct 2014
Audio: English
Subtitles: MultilingualYouTube
Audio transl.: None

If you don't see subtitles in your language, turn on auto-translate from the player's settings gear (⚙).

No subtitles in your language?

First try the player's auto-translate: settings gear (⚙) → Subtitles/CC → Auto-translate. If the video has no subtitles at all, your phone or browser can write out what is said in real time. It runs on your own device: CanduCardio receives and stores nothing.

Android phone: Settings → Accessibility → Live Caption (on many models a captions button also appears when you press the volume key). Some models, such as Pixel or recent Samsung Galaxy phones, can also translate them.
Chrome (computer or Android): Settings → Accessibility → Live Caption. For some languages it can also translate them.
Windows 11: Settings → Accessibility → Captions (or press Windows + Ctrl + L).
iPhone, iPad or Mac: Settings → Accessibility → Live Captions (depending on language and model).
TVs: almost none have this feature; use the player's auto-translate (⚙).

Educational content only. CanduCardio is intended for healthcare professionals and CanduTV for the general public. It does not replace clinical judgment or professional consultation.